Early postoperative intraperitoneal Adriamycin as an adjuvant treatment for visceral and retroperitoneal sarcoma.
Early postoperative intraperitoneal Adriamycin (doxorubicin) may be an excellent adjuvant treatment that, when combined with complete surgical removal, may markedly improve the survival of patients with visceral and retroperitoneal sarcoma. Even if its only effect were to decrease the incidence of sarcomatosis, a markedly improved quality of life for these patients would be achieved. We suggest that these improved local treatments should be combined with aggressive systemic therapy in order to develop an optimal adjuvant approach to the treatment of sarcoma. Prospective studies to test the efficacy of these treatment strategies are needed.
Sugarbaker
P H
PH
Cancer Institute, Washington Hospital Center, DC 20010, USA.
D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D004317:Doxorubicin / Q000008:administration & dosage*; D006801:Humans; D007274:Injections, Intraperitoneal; D012186:Retroperitoneal Neoplasms / Q000188:drug therapy*; D012509:Sarcoma / Q000188:drug therapy*
D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin